Role of Interleukin-18 Inflammatory Disease

Clicks: 1
ID: 309164
2025
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #97 of 153 articles by views in International Journal of Pharmaceutical Drug Design (IJPDD)

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 153 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
The family of interleukin (IL)-1 includes IL-18. The fact that both IL-1B and IL-18 need intracellular cysteine proteolytic caspase-1 for any biological activity indicates their intimate relationship. Some autoimmune illnesses are believed to be partially caused by IL-18. Interferon-G (IFN-G) is thought to be elevated in a number of conditions, such as Crohn's disorder, the skin condition, arthritis of the joints, graft vs host illness, lupus erythematosus systemic, and stimulation of macrophages syndrome. Moreover, it appears that IL-18 may be involved in ischemia, which includes acute kidney injury in humans. The role of IL-18 is demonstrated by animal models of hepatitis, graft versus target infection, plaque accumulation, and lupus erythema. Remarkably, inflammatory mediator 18 plays a part in hunger regulation and the ensuing development of obesity. It has been demonstrated that IL-18-binding proteins, a natural and selective antagonist of IL-18, in is safe for use in human patients and neutralizes IL-18 activity. Capsase-1 inhibitors, human monoclonal antibodies against IL-18, which permeable IL-18 receptors, as well as anti-IL-18 receptors polyclonal antibodies are further potential treatments for lowering IL-18 activity.
Reference Key
imported_1761926443_6904dd2ba9a74 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Shadab, Navneet Kaur*, Pawneet Sharma, Nischayjit Singh
Journal International Journal of Pharmaceutical Drug Design (IJPDD)
Year 2025
DOI
10.62896/ijpdd.2.5.10
URL
https://ijpdd.org/index.php/files/article/view/277
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.